Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay007 in Active Ulcerative Colitis
NCT03977480Phase 2Terminated
- Sponsor
- Tianjin Hemay Biotech
- Start
- Aug 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hemay007 in ulcerative colitis (UC), sponsored by Tianjin Hemay Biotech. Started Aug 2019; status: terminated.
02
Drugs
hemay007
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03977480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03977480.